Distinct Stem Cell Identities Converge into Shared Erythroid Stress in ERCC6L2 Disease and Shwachman-Diamond Syndrome
Langohr, L.; Kaaja, I.; Douglas, S.; Nebelung, H.; Koski, J.; Ikonen, I.; Katainen, L.; Maljanen, K.; Hakkarainen, M.; Räisänen, T.; Niinimäki, R.; Kakko, S.; Siitonen, T.; Adhikari, S.; Vähä-Koskela, M.; Heckman, C. A.; Lahtela, J.; Wartiovaara-Kautto, U.; Pitkänen, E.; Kilpivaara, O.
Show abstract
ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2. ED leads to accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. Given the global challenge of treating TP53-mutated AML, ED provides a unique opportunity to study early events leading to high-risk leukemia. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single-cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single-cell TP53 genotyping. We identify disease-associated erythroid delay and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman-Diamond syndrome (SDS) to reveal shared and disease-specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease-specific pattern, ED shows aberrant erythroid priming and a differentiation block in TP53-mutated cells during leukemic transformation. Taken together, we provide the first single-cell analyses in ED, define stress responses shared with SDS, and aberrant erythroid priming with TP53-driven differentiation arrest shaping progression toward erythroid leukemia. Our results give biological insights to guide therapy development aiming at intercepting disease evolution to treatment-refractory AML. Key pointsO_LIERCC6L2 disease patient cells engage maladaptive erythroid programs early in differentiation C_LIO_LICell cycle and ferroptotic stress signatures persist despite somatic TP53 mutations C_LI
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Hematopoietic fitness of JAK2 V617F Myeloproliferative Neoplasms is linked to clinical outcome 96%
- Lfc/Arhgef2 regulates mitotic spindle orientation in hematopoietic stem and progenitor cells and is essential for productive hematopoiesis 96%
- Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes 96%
Similar papers in this journal
- Epo-IGF1R crosstalk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm 96%
- CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis 96%
- Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms 96%
Similar papers in this journal
- ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis 96%
- Genome-wide CRISPR Screens Identify Ferroptosis as a Novel Therapeutic Vulnerability in Acute Lymphoblastic Leukemia 96%
- Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia 94%
Similar papers in this journal
- Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties 96%
- Mapping AML heterogeneity – multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses 96%
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.